Vocxi Health and Forj Medical partner to miniaturize graphene-enhanced breath-based diagnostic system

MyBreathPrint uses graphene-based nano sensors and machine learning based algorithms to detect volatile organic compounds (VOCs) produced by the body in a person’s breath that correspond with specific diseases, including lung cancer, the world’s leading cause of cancer death. The device’s ultra-sensitive sensors can detect compounds at parts-per-billion concentration, a thousand times more sensitive than conventional medical gas sensors. Combined with AI/ML based algorithm, the system delivers accurate, near-instant results in seconds, potentially enabling widespread screening in clinics, and ultimately, in homes.

Vocxi Health, a medical technology company developing graphene-enhanced breath-based diagnostics, has partnered with Forj Medical to transform its MyBreathPrint device from a desktop prototype into a compact, handheld diagnostic platform designed for real-world use.MyBreathPrint uses graphene-based nano sensors and machine learning based algorithms to detect volatile organic compounds (VOCs) produced by the body in a person’s breath that correspond with specific diseases, including lung cancer, the world’s leading cause of cancer death. The device’s ultra-sensitive sensors can detect compounds at parts-per-billion concentration, a thousand times more sensitive than conventional medical gas sensors. Combined with AI/ML based algorithm, the system delivers accurate, near-instant results in seconds, potentially enabling widespread screening in clinics, and ultimately, in homes.

Read More Graphene-Info – Graphene industry portal